{"abstract_id": 2892, "endpoint_id": 125, "truth": 1, "pred": 1, "blended_prob": 0.6020000000000001, "llm_prob": 0.42, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient safety data in retrieved evidence to confirm absence of new safety signals"], "green": []}, "rationale": "The provided trial abstract states no new safety signals, but none of the retrieved evidence excerpts contain safety information for this study, leaving the decision rule unsupported by the available citations.", "citations": [{"title": "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", "url": "https://recist.eortc.org/recist/wp-content/uploads/sites/4/2017/03/Manuscript_IRECIST_Lancet-Oncology_Seymour-et-al_revision_FINAL_clean_nov25.pdf"}]}
{"abstract_id": 1698, "endpoint_id": 100, "truth": 1, "pred": 1, "blended_prob": 0.729448275862069, "llm_prob": 0.71, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target fgfr1-3 tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the specific ORR result and p\u2011value is not present in the retrieved snippets; decision relies on trial description alone."], "green": []}, "rationale": "The trial reports an ORR of 20.0% in Group B with a one\u2011sided p\u2011value of 0.0362, which is below the 0.05 threshold required to reject the null hypothesis of \u22645% response. Despite the lack of a direct citation in the retrieved evidence, the provided trial details clearly indicate that the primary endpoint was met.", "citations": [{"title": "RECIST 1.1: Response Evaluation Criteria in Solid Tumors (Guidelines)", "url": "https://project.eortc.org/recist/wp-content/uploads/sites/4/2015/03/RECISTGuidelines.pdf"}]}
{"abstract_id": 4719, "endpoint_id": 247, "truth": 1, "pred": 1, "blended_prob": 0.63, "llm_prob": 0.65, "base_prob": 0.6, "base_note": "Base rate from unknown / co-primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["insufficient citation evidence for biomarker findings"], "green": []}, "rationale": "The trial reports that immunological biomarkers (Th7R and Th2) significantly influenced progression\u2011free and overall survival for osimertinib, demonstrating successful exploration of biomarkers as a co\u2011primary endpoint, although the retrieved external evidence does not directly document these findings.", "citations": []}
{"abstract_id": 3679, "endpoint_id": 190, "truth": 1, "pred": 1, "blended_prob": 0.79, "llm_prob": 0.85, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for irAE rates comes from trial description not from retrieved external sources"], "green": []}, "rationale": "The randomized phase 2 trial with 150 patients reported immune\u2011related adverse events in 5 (6.7%) patients in the toripalimab arm and none in the control arm, with a p\u2011value of 0.058, which meets the decision rule of no significant difference (p\u202f\u2265\u202f0.05). Sample size and randomization are adequate for this safety comparison.", "citations": []}
{"abstract_id": 1825, "endpoint_id": 271, "truth": 1, "pred": 1, "blended_prob": 0.7669999999999999, "llm_prob": 0.82, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target wee1 kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial report states that no major changes were observed in etoposide exposure across Debio 0123 dose levels, and PK data matched historical values, directly supporting the decision rule of absence of major changes.", "citations": []}
{"abstract_id": 1288, "endpoint_id": 76, "truth": 1, "pred": 1, "blended_prob": 0.8955000000000001, "llm_prob": 0.93, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target ep4 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial reports that no treatment-related serious or grade >3 adverse events occurred among the 27 enrolled patients, directly satisfying the primary safety decision rule.", "citations": []}
{"abstract_id": 6202, "endpoint_id": 48, "truth": 1, "pred": 1, "blended_prob": 0.782, "llm_prob": 0.72, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target thrombopoietin receptor not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["limited direct citation evidence for this endpoint"], "green": []}, "rationale": "The phase 3 randomized trial (N=165) compared romiplostim to placebo in patients with chemotherapy\u2011induced thrombocytopenia. Median time to first platelet response was 1.1 weeks for romiplostim versus 2.1 weeks for placebo, with a reported p\u2011value <0.001, satisfying the superiority decision rule (p < alpha). The study size and randomization support robustness of the finding.", "citations": []}
{"abstract_id": 2329, "endpoint_id": 122, "truth": 0, "pred": 1, "blended_prob": 0.8461176470588236, "llm_prob": 0.92, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["small sample size (n=16 evaluable, 7 with DDR mutations)", "single\u2011arm exploratory design without a control group"], "green": []}, "rationale": "The exploratory analysis reported a log\u2011rank P value of 0.519 for PFS comparison between DDR\u2011mutated and non\u2011mutated patients, which exceeds the pre\u2011specified significance threshold of 0.05. Given the very limited sample size and lack of a comparator arm, the endpoint does not meet the decision rule.", "citations": [{"title": "RECIST 1.1: Response Evaluation Criteria in Solid Tumors (Guidelines)", "url": "https://project.eortc.org/recist/wp-content/uploads/sites/4/2015/03/RECISTGuidelines.pdf"}]}
{"abstract_id": 3719, "endpoint_id": 287, "truth": 1, "pred": 1, "blended_prob": 0.635, "llm_prob": 0.6, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient citation for emotional well\u2011being result; trial data not present in retrieved evidence"], "green": []}, "rationale": "The trial reports a p\u2011value of 0.045 for the emotional\u2011well\u2011being improvement, which meets the predefined significance threshold of <0.05. However, the supporting data are not found in the retrieved external evidence, reducing confidence in the assessment.", "citations": []}
